Hofbic 7.5 Drug Interactions

ACE Inhibitors and Angiotensin II Receptor Antagonists: Potential pharmacologic interaction (antagonized antihypertensive effects).
Bile Acid Sequestrants: Pharmacokinetic interaction (increased meloxicam clearance; clinical importance not established) when meloxicam is used with bile acid sequestrants (e.g., cholestyramine).
Cimetidine: Pharmacokinetic interaction unlikely.
Digoxin: Pharmacokinetic interaction unlikely.
Diuretics: Patients receiving diuretics may have an increased risk of developing renal failure secondary to decreased renal blood flow resulting from prostaglandin inhibition by NSAIDs.
NSAIDs: May reduce the natriuretic effects of furosemide and thiazides. Observe patient for signs of renal failure and for diuretic effects.
Drugs Affecting Hepatic Microsomal Enzyme: Inhibitors or inducers of CYP2C9 or 3A4; interaction unlikely.
Lithium: Pharmacokinetic interaction (increased plasma lithium concentration).
Methotrexate: Potential pharmacokinetic interaction (enhanced toxicity of methotrexate resulting from inhibition of methotrexate renal elimination).
Aspirin: Concomitant use of aspirin increases serum meloxicam concentrations; clinical importance of this interaction is unknown. Concomitant use of aspirin and NSAIDs increases the risk for serious GI events. Because of the potential for increased adverse effects, concurrent use of meloxicam and aspirin generally is not recommended. Meloxicam is not a substitute for aspirin for cardioprophylaxis. There is no consistent evidence that use of low-dose aspirin mitigates the increased risk of serious cardiovascular events associated with NSAIDs.
Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic. Concomitant use of NSAIDs and warfarin is associated with a higher risk of GI bleeding compared with use of either agent alone. Caution advised if HOFBIC 7.5 is used concomitantly with warfarin.